High Dose Rate Brachytherapy monotherapy versus External Beam Radiotherapy with HDR Brachytherapy Boost for Unfavorable Intermediate Prostate Cancer Patients

Files

Authors

Doyle Lang, Beaumont Health Resident
Benjamin Willen, Beaumont Health Resident
Daniel J. Krauss, Beaumont Health Resident
Sirisha R. Nandalur, Beaumont Health

Description

Prostate cancer is the most common male malignancy by incidence in the world. Treatment differs by the patient’s risk stratification. For the treatment of unfavorable intermediate-risk prostate cancer, external beam radiotherapy with high-dose-rate brachytherapy boost was the accepted treatment but high-dose-rate brachytherapy as monotherapy has been proposed as a potentially viable treatment option. External beam radiotherapy treatment involves shooting high-energy photons or particle radiation through normal healthy tissue to hit the tumor directly. High-dose-rate brachytherapy involves inserting radioactive seeds into the tumor. Studies are needed to compare toxicity profiles and relative outcomes between the two treatment options.

Publication Date

5-2023

Keywords

Prostate cancer

Disciplines

Oncology | Radiation Medicine

Recommended Citation

Lang D, Willen B, Krauss D, Nandalur S. High dose rate brachytherapy monotherapy versus external beam radiotherapy with HDR brachytherapy boost for unfavorable intermediate prostate cancer patients. Poster presented at: Oakland University William Beaumont School of Medicine Embark Capstone Colloquium; 2023 May; Rochester Hills, MI.

Comments

The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May, 2023.